Corona Remedies Q2FY26 Results: Revenue Grows 15.1% with Earnings Call on Jan 5
Corona Remedies delivered robust Q2FY26 performance with revenue growth of 15.1% to ₹361.13 crores and profit after tax surge of 21.8% to ₹52.32 crores. The company maintained strong profitability metrics with EBITDA margin at 21.7% and announced an earnings call scheduled for January 5, 2026 at 12:00 PM IST to discuss financial results and business developments.
*this image is generated using AI for illustrative purposes only.
Corona Remedies Limited has filed its unaudited financial results for the second quarter and half-year ended September 30, 2025, with stock exchanges under Regulation 33 of SEBI Listing Regulations. The Board of Directors approved these results at their meeting held on January 2, 2026, demonstrating strong operational performance across key financial metrics.
Strong Q2FY26 Financial Performance
The pharmaceutical company delivered impressive consolidated results for Q2FY26, with revenue from operations reaching ₹361.13 crores, representing robust 15.1% year-on-year growth. Net profit after tax surged 21.8% to ₹52.32 crores, showcasing the company's operational efficiency.
| Metric | Q2FY26 | Q2FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations | ₹361.13 cr | ₹313.87 cr | +15.1% |
| EBITDA | ₹78.47 cr | ₹66.50 cr | +18.0% |
| EBITDA Margin | 21.70% | 21.18% | +52 bps |
| Net Profit After Tax | ₹52.32 cr | ₹42.97 cr | +21.8% |
| Profit After Tax Margin | 14.50% | - | - |
Half-Year Performance Highlights
For the half-year period H1FY26, Corona Remedies maintained strong momentum with revenue from operations growing 17.0% year-on-year to ₹707.67 crores. Profit after tax increased significantly by 35.1% to ₹98.52 crores, reflecting improved operational leverage.
| Parameter | H1FY26 | H1FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations | ₹707.67 cr | ₹605.04 cr | +17.0% |
| EBITDA | ₹148.25 cr | - | - |
| EBITDA Margin | 20.90% | - | - |
| Net Profit After Tax | ₹98.52 cr | ₹72.92 cr | +35.1% |
| Profit After Tax Margin | 13.90% | - | - |
Key Financial Ratios and Metrics
Corona Remedies demonstrated strong return ratios for H1FY26 with annualized Return on Equity at 31.1% and Return on Capital Employed at 49.7%. The company maintained efficient working capital management with net working capital days at 23 days and operating cash flow to EBITDA ratio at 76.5%.
| Financial Metric | H1FY26 |
|---|---|
| Return on Equity (Annualized) | 31.10% |
| Return on Capital Employed (Annualized) | 49.70% |
| OCF to EBITDA | 76.50% |
| Net Working Capital Days | 23 Days |
Management Commentary and Outlook
Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, highlighted the company's outperformance against Indian Pharmaceutical Market growth. He emphasized the consistency of strategy, disciplined execution, and focus on core therapeutic segments including strengthening field force, expanding brand portfolio, and maintaining focus on specialist prescriptions.
Earnings Call Announcement
Corona Remedies will conduct an earnings call on January 5, 2026, at 12:00 PM IST to discuss the financial and business performance for Q2FY26. The company has provided multiple dial-in numbers for domestic and international participants.
| Earnings Call Details | Information |
|---|---|
| Date & Time | January 5, 2026 at 12:00 PM IST |
| Universal Dial-In | +91-22-6280 1366 / +91-22-7115 8267 |
| USA | 1 866 746 2133 |
| UK | 0 808 101 1573 |
| Singapore | 800 101 2045 |
Company Profile and Operations
Founded in 2004, Corona Remedies operates WHO-GMP and EU GMP-certified manufacturing facilities with two DSIR-approved R&D centers employing over 4,500 people. The company focuses on multiple therapeutic areas including women's healthcare, cardio-diabeto, pain management, and urology. Corona Remedies completed its Initial Public Offering and listed on NSE and BSE on December 15, 2025.
15
